QualityDipStocks / Health Care · Pharmaceuticals
Cronos Group Common Share CRON
Outside our quality screen, so we don’t track its dips. It’s 6% below its 52-week high.
Outside our quality screen, trading below our fair value estimate.
- Fair value est.
- $4.10+23%
- Market Value
- $3.32at the price
- Off 52-wk high
- −6%
- Risk vs market
- Lowbeta 0.60
52-week range 82% of the way from its 52-week low to its high
Price $3.33Fair value est. $4.10Market Value $3.32
5 bullish · 4 bearish See why
Repriced or dip?
Near its high
The price is 6% below its 52-week high (Aug 26), but the business held up: shares outstanding unchanged, operating margin 0.0 pts, free cash flow 0.0%.
Some numbers held up (shares outstanding unchanged, operating margin 0.0 pts, free cash flow 0.0%), others slipped. The price is 6% below its 52-week high.
The price is 6% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($3.55, Aug 26) the price assumed about 12%/yr free-cash-flow growth; today about 11%. The last 3 years delivered 19%/yr (revenue).
Dashed line: what the last 3 years delivered, 19%/yr (revenue)
| High | Low | Now | |
|---|---|---|---|
| Price | $3.55Aug 26 | $2.30Nov 20 | $3.33 |
| Implied growth | +12% | n/a | +11% |
| P/E | 19.0× | 24.5× | 17.8× |
| P/FCF | 26.7× | — | 25.1× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, CRON’s free cash flow would need to grow about 11% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much CRON moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 3.1× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.60
- Volatility
- 40% vs 13% SPY
- Correlation SPY
- 0.19
- Correlation QQQ
- 0.14
How it ranks
Where CRON stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 5 measures
- Discount to fair value estimate23% · price below our base caseTop 33%of 1,507
- Free cash flow yield4% · free cash flow vs market capTop 50%of 1,690
- Dividends + buybacks yield3.1% · cash paid out or used to retire shares, vs market capTop 44%of 2,227
- Revenue growth, last 12 months+37% · vs the 12 months beforeTop 11%of 2,184
- Operating margin−1.4% · of sales kept as operating profitLowest 14%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
DCF $4.10 · MV $3.32 · FCF value $0.69
Assumes 15.0% growth for 5 years (revenue grew 19.1% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $0.13 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 6, 2026.
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ProfitabilityGross margin widened to 42.8% in FY2025 from 13.7% in FY2023 (SEC filings).
ProfitabilityOperating margin widened to −11.9% in FY2025 from −97.2% in FY2023 (SEC filings).
ValuationOur DCF fair value estimate is $4.10, 23% above the price.
GrowthSales grew 37% to $179M over the last 12 months vs the 12 months before (SEC filings).
ValuationP/E of 17.8× vs a 28.9× median for the 161 Health Care companies we cover.
Top bearish points 4 of 5
ProfitabilityLoses money at the operating line: −1% operating margin over the last 12 months.
ProfitabilityReturn on equity is only 7% over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
RiskReports earnings Nov 5 (consensus EPS $0.03): results can move the price sharply and reset Market Value.
All fundamentals
P/E 17.8 · FCF yield 4.0% · ROE 7%
Valuation
- P/E
- 17.8×Health Care median 28.9×
- Price / FCF
- 25.1×
- FCF yield
- 4.0%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 6.97×
- Price / book
- 1.17×
- Market cap
- $1.2Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $179M
- Sales growth, 12 months
- +37.5%vs the 12 months before
- Sales growth, 3 yrs
- +19.1%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.19
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $70M
- Net income growth
- +278%12 months vs before
Profitability
- Gross margin
- 45.9%
- Operating margin
- −1.4%
- Net margin
- 39.1%
- FCF margin
- 27.8%
- Return on equity
- 7%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $797M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $50M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $39M3.1% of market cap
- Share count, 1 year
- −2.7%diluted shares vs a year ago
- Stock-based comp
- $6M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Cronos Group Common Share’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +58%
- Free cash flow, 12 months$0.0B
- Free-cash-flow yield4.0%
- Free-cash-flow margin3%
- Gross margin43%
- Operating margin15%
- Return on invested capital8%
- Return on equity7%
- Sales growth (latest quarter vs year-ago quarter)+58%
- Net debt / EBITDA−67.0×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $3.33
- 52-wk lowlowest close, 1 year$2.30−30.9%
- Market Valueavg paid since Oct 15$3.32−0.3%
- PriceMon Nov 2 close$3.33you are here
- 52-wk highhighest close, 1 year$3.55+6.6%
- Fair value est.base case$4.10+23.1%
Momentum & 52-week range
RSI 53 · 5 days +0.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$0.03
- Year-ago EPS$0.07
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
CRON is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Cronos Group Common Share in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.